Updates in head and neck cancers

First-line pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma

Cisplatin superior to cetuximab for HPV oropharyngeal cancer

Cisplatin v cetuximab for HPV associated oropharyngeal cancer

KEYNOTE048: First line pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma

ESMO 2018: Highlights

The promise of immunotherapy in head and neck, and prostate cancer

MyPathway study: a novel precision oncology multiple basket trial

Editor's Choice for June 2018

Novel fusion proteins to target PD-L1 in HPV associated cancers

Phase I study results of M7824 for patients with HPV associated cancers

Comment: Aspirin with acid-reducing medicine reduces chance of oesophageal cancer in high risk individuals